Drug
Sirolimus clinical trials
Also written Rapamycin, Rapamune, AY 22989 and SILA 9268A.
- studies test it
- 520
- open now
- 86
- in phase 3
- 76
- first study started
- 1996
Keep track of what changes. Save the Sirolimus studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AY 22989
- 31
Combined with it in one product
Studies by the year they started
513 studies that test it; most in 2006 (34); 2 more planned to start later
| Year | Studies |
|---|---|
| 1996 | 2 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 9 |
| 2001 | 7 |
| 2002 | 17 |
| 2003 | 7 |
| 2004 | 19 |
| 2005 | 21 |
| 2006 | 34 |
| 2007 | 25 |
| 2008 | 24 |
| 2009 | 21 |
| 2010 | 28 |
| 2011 | 20 |
| 2012 | 20 |
| 2013 | 16 |
| 2014 | 18 |
| 2015 | 17 |
| 2016 | 17 |
| 2017 | 23 |
| 2018 | 23 |
| 2019 | 13 |
| 2020 | 19 |
| 2021 | 18 |
| 2022 | 20 |
| 2023 | 10 |
| 2024 | 18 |
| 2025 | 22 |
| 2026 | 23 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 19
- Phase 1
- 161
- Phase 2
- 263
- Phase 3
- 76
- Phase 4
- 71
- No phase
- 27
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 67 · Other 453
Wyeth is now a wholly owned subsidiary of Pfizer (22) · National Institute of Allergy and Infectious Diseases (NIAID) (19) · Mayo Clinic (12) · The University of Texas Health Science Center at San Antonio (10) · National Cancer Institute (NCI) (9) · University of Chicago (9) · Peking Union Medical College Hospital (9) · National Heart, Lung, and Blood Institute (NHLBI) (8)
Often tested with
Tested in the same studies.
Tacrolimus (55) · Cyclophosphamide (28) · Mycophenolic Acid (27) · Cyclosporine (22) · Alemtuzumab (20) · Fludarabine (14) · Methotrexate (10) · Antilymphocyte Serum (10)
Studies
Open first, then newest update. How each study uses Sirolimus is read from its arms, and is right about nine times in ten.
Testing it · 520
- Advancing Transplantation Outcomes in ChildrenRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06055608Written as Sirolimus
- Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsRecruitingPhase 2/3Katarzyna KotulskaNCT04987463Written as Rapamycin
- Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment InterruptionNot yet recruitingPhase 2ANRS, Emerging Infectious DiseasesNCT07081763Written as Sirolimus 2 MG
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingPhase 1/2National Cancer Institute (NCI)NCT05436418Written as Sirolimus
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingPhase 1Umoja BiopharmaNCT06528301Written as rapamycin
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT05896839Written as Sirolimus
- Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet DisorderRecruitingPhase 1OHSU Knight Cancer InstituteNCT07844694Written as Sirolimus
- A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesRecruitingPhase 1/2Umoja BiopharmaNCT07735533Written as Rapamycin (sirolimus)
- Effects of Sirolimus on Asymptomatic ApoE4 CarriersRecruitingPhase 1University of Missouri-ColumbiaNCT07728175Written as Sirolimus (rapamycin)
- Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyRecruitingPhase 2Darcy KruegerNCT05104983Written as Sirolimus
- Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.Not yet recruitingPhase 1/2University Hospital, Strasbourg, FranceNCT07853105Written as Dinutuximab beta, Sirolimus and Irinotecan
- Sirolimus Discontinuation Strategies in Kaposiform HemangioendotheliomaRecruitingPhase 2West China HospitalNCT07131644Written as Sirolimus
- Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)Not yet recruitingPhase 2Case Comprehensive Cancer CenterNCT06084780Written as Sirolimus
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisRecruitingPhase 1/2National Human Genome Research Institute (NHGRI)NCT03952637Written as Sirolimus
- A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)Not yet recruitingPhase 1/2Cedars-Sinai Medical CenterNCT06682767Written as Rapamycin
- A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.Not yet recruitingEarly Phase 1Northwestern UniversityNCT07813533Written as sirolimus topical gel 0.2%
- Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet DisorderRecruitingPhase 2M.D. Anderson Cancer CenterNCT06261060Written as Sirolimus
- Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNINot yet recruitingPhase 1/2Peking University People's HospitalNCT07796620Written as Sirolimus
- Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseEnrolling by invitationPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT07113743Written as Sirolimus
- Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need VentilatorsRecruitingPhase 1/2Astellas Gene TherapiesNCT07052929Written as Sirolimus
See all 520 studies that test Sirolimus →
Given in every arm · 73 — Sirolimus is usual care beside what is tested
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingPhase 2Fred Hutchinson Cancer CenterNCT03970096Written as Sirolimus
- Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT05327023Written as Sirolimus
- Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesRecruitingPhase 1/2National Cancer Institute (NCI)NCT04959175Written as Sirolimus
- Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationRecruitingPhase 1National Cancer Institute (NCI)NCT07162038Written as Sirolimus
- Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingPhase 2Washington University School of MedicineNCT07715734Written as Sirolimus
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) AntagonistsRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05463133Written as Sirolimus
- Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationRecruitingPhase 2University of NebraskaNCT06799195Written as Sirolimus
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeRecruitingPhase 2City of Hope Medical CenterNCT07582172Written as Sirolimus
- Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing SettingRecruitingPhase 4Sarepta Therapeutics, Inc.NCT07542314Written as Sirolimus
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingPhase 4Dana-Farber Cancer InstituteNCT07426484Written as Sirolimus
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingPhase 1City of Hope Medical CenterNCT06287944Written as Sirolimus
- Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant DiseasesRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT04083183Written as Sirolimus
- 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)RecruitingPhase 1Columbia UniversityNCT07015684Written as Sirolimus
- Effect of Sirolimus on Molecular Alterations in Cerebral AneurysmsRecruitingPhase 2University of MiamiNCT04141020Written as Sirolimus
- A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid TumorsRecruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07241936Written as sirolimus (albumin-bound)
- Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodyRecruitingPhase 2Children's National Research InstituteNCT06358638Written as Sirolimus
- Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin ARecruitingPhase 2Peking Union Medical College HospitalNCT06802055Written as Sirolimus (Rapamune®)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT00792948Written as Sirolimus
- Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaCompletedPhase 1City of Hope Medical CenterNCT01163357Written as sirolimus
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant CyclophosphamideActive, not recruitingEarly Phase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03910452Written as Sirolimus
Showing 20 of 73.
As the comparator · 6 — what is tested is compared with Sirolimus
- MTOR Inhibitors in Older AdultsRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06727305Written as Sirolimus 0.5 Mg Oral Tablet
- Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)TerminatedPhase 2University of LiegeNCT01903473Written as Rapamycin
- A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic CancerCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02048384Written as rapamycin (Arm B)
- Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + CorticosteroidsCompletedPhase 4PfizerNCT01601821Written as CsA+Rapamune+CS
- Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant PatientsWithdrawnPhase 4University of Colorado, DenverNCT02062892Written as Sirolimus
- Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver TransplantCompletedPhase 4Hoffmann-La RocheNCT00118742Written as Sirolimus
Codes
What other systems call Sirolimus · ClinicalTrials.gg INT008754
- MeSH (NLM) D020123SirolimusConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) W36ZG6FT64SIROLIMUSConfirmed FDA, NLM, Wikidata
- RxNorm 35302Confirmed FDA, Wikidata
- Wikidata Q32089sirolimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1212SirolimusConfirmed FDA, Wikidata
- DrugBank DB00877One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D020123 | Sirolimus | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | W36ZG6FT64 | SIROLIMUS | Confirmed FDA, NLM, Wikidata |
| RxNorm | 35302 | — | Confirmed FDA, Wikidata |
| Wikidata | Q32089 | sirolimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1212 | Sirolimus | Confirmed FDA, Wikidata |
| DrugBank | DB00877 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.